This case demonstrates achievement of a significant and sustained complete response in a patient with advanced HER2-amplified lung adenocarcinoma who was treated with the combination of cadonilimab and disitamab vedotin, after declining conventional chemotherapy. Here, ERBB2 is linked to lung adenocarcinoma.